{"schema_version":"secwatch.filing_event.v1","accession":"0000950170-23-049046","form_type":"8-K","ticker":"ELDN","cik":"0001404281","company_name":"Eledon Pharmaceuticals, Inc.","filed_at":"2023-09-21T23:59:59+00:00","discovered_at":"2026-05-14T18:03:33.807042+00:00","generated_at":"2026-06-10T10:30:12.863050+00:00","sec_items":["5.02","9.01"],"event_type":"other","sentiment":"neutral","materiality_score":0.1,"calibrated_materiality_score":0.1,"confidence":"high","headline":"Eledon Pharmaceuticals adopts updated director and officer indemnification agreement","bullets":["Board approved new form of indemnification agreement for all directors and officers.","Agreement provides indemnification to the maximum extent permitted by Delaware law.","New agreement replaces existing indemnification agreements in place with directors and executive officers.","No departures, elections, or appointments of officers were announced.","Indemnification rights are in addition to any rights under certificate of incorporation or bylaws."],"urls":{"canonical":"https://secwatch.observer/filing/0000950170-23-049046","json":"https://secwatch.observer/filing/0000950170-23-049046.json","markdown":"https://secwatch.observer/filing/0000950170-23-049046.md","text":"https://secwatch.observer/filing/0000950170-23-049046.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1404281/000095017023049046/0000950170-23-049046-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1404281/000095017023049046/eldn-20230920.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-10T10:30:12.863050+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}